Back to Search Start Over

Biosimilars production in Africa opportunities & challenges.

Authors :
Abdel-Maged AE
Mikhaeil MF
Elkordy AI
Gad AM
Elshazly MM
Source :
Regulatory toxicology and pharmacology : RTP [Regul Toxicol Pharmacol] 2024 May; Vol. 149, pp. 105626. Date of Electronic Publication: 2024 Apr 16.
Publication Year :
2024

Abstract

The healthcare systems of African nations heavily rely on importing and repackaging biological medicine. More than 70% of the pharmaceutical products consumed in Africa are imported. The localization of biosimilar production can have a positive impact on the availability and cost of these products by reducing the expenses for African governments and making essential healthcare products more accessible to the population. However, it is evident that the developing countries, particularly African nations, face various obstacles and difficulties in localizing biosimilar production. These challenges encompass development, manufacturing, evaluation, and registration processes. In this review, we will highlight the significant hurdles and achievements encountered during the localization process of biosimilars.<br />Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.<br /> (Copyright © 2024 Elsevier Inc. All rights reserved.)

Details

Language :
English
ISSN :
1096-0295
Volume :
149
Database :
MEDLINE
Journal :
Regulatory toxicology and pharmacology : RTP
Publication Type :
Academic Journal
Accession number :
38636774
Full Text :
https://doi.org/10.1016/j.yrtph.2024.105626